This study is investigating a new administration schedule of Rituximab, Cyclophosphamide,
Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse
Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up;
certain participants 70-74 may be eligible) that is often excluded from clinical trials.
Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of
post treatment follow-up).